Publication date: Jul 14, 2024
Background Immunocompromised patients are at high risk of developing persisting/prolonged COVID-19. Data concerning early combined use of antivirals and monoclonal antibodies in this population are scarce. Research design and methods We performed an observational, prospective study, enrolling immunocompromised outpatient adults with mild-to-moderate COVID-19 treated with a combination of sotrovimab plus one antiviral (remdesivir or nirmatrelvir/ritonavir) within 7 days from symptoms onset. Results We enrolled 52 patients. No patient was hospitalized within 30 days from the disease onset, needed oxygen administration or died within 60 days, or experienced a reinfection or a clinical relapse within 90 days. Clearance rates were 67% and 97% at 14th day after the end of therapy and at the end of follow-up, respectively. Factors associated with longer infection were initiation of therapy after 3 days from symptoms onset, and enrollment more than 180 days from the beginning of the study. However, only the latter factor was independently associated with longer SARS-CoV-2 infection, suggesting a loss of efficacy of this strategy with the evolution of SARS-CoV-2 variants Conclusions Early administration of combination therapy with a direct antiviral and sotrovimab seems to be effective in preventing hospitalization, progression to severe COVID-19 and the development of prolonged/persisting SARS-CoV-2 infection in immunocompromised patients.
| Concepts | Keywords |
|---|---|
| Biotechnology | Clinical |
| Chicago | Combination |
| Immunosuppressive | Cov |
| July | Covid |
| Days | |
| Early | |
| Immunocompromised | |
| Infection | |
| Onset | |
| Patient | |
| Preprint | |
| Prolonged | |
| Sars | |
| Symptoms | |
| Therapy |